Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-04-04
2006-04-04
Fredman, Jeffrey (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023100, C536S024300
Reexamination Certificate
active
07022478
ABSTRACT:
This invention relates to the use of a blood sample from a patient for evaluating stroke or cardiac ischemia in the patient.
REFERENCES:
patent: 6329179 (2001-12-01), Kopreski
patent: WO 98/14617 (1998-04-01), None
patent: WO 01/42504 (2001-06-01), None
patent: WO 02/02812 (2002-01-01), None
patent: WO 03/009806 (2003-02-01), None
Fournie, G. J. et al., “Plasma DNA as Cell Death Marker in Elderly Patients”, Gerontology, vol. 39, pp. 215-221 (1993).
Wijeratne, S. et al., “Cell-Free Plasma DNA as a Prognostic Marker in Intensive Treatment Unit Patients”, Ann. N.Y. Acad. Sci. vol. 1022, pp. 232-238 (2004).
Abraha, H.D. et al. “Serum S-100 protein, relationship to clinical outcome in acute stroke,”Ann. Clin. Biochem. 1997, pp. 366-370, vol. 34.
Büttner, T. et al. “S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction,”Stroke1997, pp. 1961-1965, vol. 28.
Chen, X. Q. et al. “Microsatellite alterations in plasma DNA of small cell lung cancer patients,”Nat. Med. 1996, pp. 1033-1035, vol. 2.
Dasi, F. et al. “Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients,”Laboratory Invest. may 2001, pp. 767-769, vol. 81, No. 5.
Lo, Y.M.D. et al. “Plasma DNA as a prognostic marker in trauma patients,”Clin. Chem. 2000, pp. 319-323, vol. 46, No. 3.
Lo, Y.M.D. et al. “Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma,”N. Engl. J. Med. 1998, pp. 1734-1738, vol. 339.
Lo, Y.M.D. et al. “Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients,”Lancet1998, pp. 1329-1330, vol. 351.
Lo, Y.M.D. et al. “Presence of fetal DNA in maternal plasma and serum,”Lancet1997, pp. 485-487, vol. 350.
Lo. Y.M.D. et al. “Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis,”Am. J. Hum. Genet. 1998, pp. 768-775, vol. 62.
Nawroz, H. et al. “Microsatellite alterations in serum DNA of head and neck cancer patients,”Nat. Med. 1996, pp. 1035-1037, vol. 2.
Nomoto, S. et al. “Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma,”Clin. Can. Res. Feb. 2002, pp. 481-487, vol. 8.
Stevens, H. et al. “Neurone-specific enolase and N-acetyl-aspartate as potential peripheral markers of ischaemic stroke,”Eur. J. of Clin. invest. 1999, pp. 6-11, vol. 29.
Wunderlich, M.T. et al. “Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage,”Stroke1999, pp. 1190-1195, vol. 30.
Zhong, S. et al. “Presence of mitochondrial tRNALeu(UUR) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus,”J. Clin. Pathol. 2000, pp. 466-469, vol. 53.
Lam Yuk Lan
Lo Yuk Ming Dennis
Rainer Timothy Hudson
Wong Lawrence Ka Sing
Fredman Jeffrey
Strzelecka Teresa
The Chinese University of Hong Kong
LandOfFree
Methods for evaluating stroke or cardiac ischemia by nucleic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for evaluating stroke or cardiac ischemia by nucleic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for evaluating stroke or cardiac ischemia by nucleic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557612